Development of a market relevant DNA nano-vaccine platform

开发与市场相关的 DNA 纳米疫苗平台

• 批准号: LP200201078
• 负责人: Prof Chengzhong Yu
• 金额: $ 26.99万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-08-10 至 2025-01-31
• 项目状态: 未结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP200201078
• 关键词: Development; market; relevant; DNA; nano

DNA vaccine technology can potentially provide a rapid response to existing or new pathogens, but its market success has been limited. By addressing key scientific and technical challenges, this project aims to develop a new and cost-effective DNA nanovaccine platform using a multiscale engineering approach. It is anticipated that novel nanoparticles for DNA delivery and an end-user-driven DNA vaccine technology with enhanced immunogenicity, stability and safety will be generated. Expected outcomes include new knowledge in nanomaterial science and a market ready technology platform, improving Australia’s capabilities in nanobiotechnology and vaccine development, as well as delivering a new value-added product for the Industry Partner.

DNA 疫苗技术有可能对现有或新的病原体做出快速反应，但其市场成功有限。通过解决关键的科学和技术挑战，该项目旨在利用多尺度工程方法开发一种新型且具有成本效益的 DNA 纳米疫苗平台。预计将产生用于 DNA 递送的新型纳米粒子和具有增强免疫原性、稳定性和安全性的最终用户驱动的 DNA 疫苗技术。预期成果包括纳米材料科学的新知识和市场就绪的技术平台，从而提高澳大利亚在纳米生物技术方面的能力。和疫苗开发，以及为行业合作伙伴提供新的增值产品。